0000000000920944
AUTHOR
P De Simone
Search for CP violation in D (+/-) -> (KSK +/-)-K-0 and D-s(+/-) -> K-S(0)pi(+/-) decays
A search for \CP violation in Cabibbo-suppressed $D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}$ and $D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}$ decays is performed using $pp$ collision data, corresponding to an integrated luminosity of 3~fb$^{-1}$, recorded by the LHCb experiment. The individual $CP$-violating asymmetries are measured to be \begin{eqnarray*} \mathcal{A}_{CP}^{D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}} & = & (+0.03 \pm 0.17 \pm 0.14) \% \mathcal{A}_{CP}^{D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}} & = & (+0.38 \pm 0.46 \pm 0.17) \%, \end{eqnarray*} assuming that $CP$ violation in the Cabibbo-favoured decays is negligible. A combination of the measured asymmet…
Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in…